July 13,
2022
1390
The Excellence Index 2020 results were released on 18th of February. Quilaban began on this path seven years ago and recently extended the challenge to all of the Group's companies. For the second year in a row, Quilaban ranked first among pharmaceutical companies in 2020, with a value of 81 percent.
Our International Companies had a value of 78.4 percent, Pharmacies had a value of 77.5 percent, and our Clinics had a value of 70.3 percent.
June 28,
2022
1496
Illumina has joined the Business Ambition for 1.5°C campaign, a global coalition led by the UN Global Compact, Science Based Targets and We Mean Business Coalition.
June 28,
2022
1307
Every year, Fast Company magazine compiles a list of the 50 most innovative companies in the world across various business sectors.
June 28,
2022
1378
Illumina recognized Quilaban with the "2021 – Elite Status Award." This distinction is the result of an extraordinary year of work by Quilaban, which saw a 56 % increase in revenue from 2020 to 2021, exceeding the company's own target set by Illumi
June 2,
2020
4400
Estamos no TOP 15 do estudo da Happiness Works e não poderíamos estar mais felizes e orgulhosos com esta conquista.
Ser uma empresa feliz é, para nós, valorizar o bem-estar, promover o espírito de equipa e cooperação e criar condições à felicidade individual dos nossos colaboradores.
Acreditamos que uma empresa feliz é feita de pessoas felizes, realizadas na empresa e nas suas vidas.
May 18,
2020
5057
Na sequência da notícia publicada pelo jornal Público no dia 17 de maio com o título “Três milhões de máscaras compradas com certificado falso” e replicada por diversos meios de comunicação social, a Quilaban esclarece o seguinte:
Para satisfazer o contrato de fornecimento à Direção Geral de Saúde (DGS), por ajuste direto dos Serviços Partilhados do Ministério da Saúde (SPMS), de três milhões de máscaras FF92 /KN95, a Quilaban recorreu à produção da Gansu Changee Bio-pharmaceutical Co., Ltd. (Gansu).
May 10,
2020
3962
Taking into account all the difficulties that we need to overcome in order to export the goods, we are very proud to announce that we are implementing our purpose which is to care for the health and well-being of people like us across the border.
Before we had already supplied rapid tests and other products for the diagnostic and fight against COVID-19 in external markets, but now we are also participating actively in this fight in Cape Verde, by means of the supply of 30.000 rapid tests to EMPROFAC.
May 10,
2020
4019
Last month we were formally awarded the second GeneReader™NGS system in Portugal, at the Centro Hospitalar de Trás os Montes e Alto Douro (CHTMAD), in the city of Vila Real.
This was only possible through hard team work hat reinforces Quilaban’s position in the field of Diagnostics for Oncology.
The NGS Qiagen workflow is designed for clinical diagnostics and aims to give a fast, simple, optimized response with maximum relevant Information to our oncologists.
April 26,
2020
3998
“Confidence in our path wo the new normal” – With this purpose in mind, we dedicated ourselves to build a complementary solution to the preventive measures against COVID-19 contamination.
Because a rapid test approaches the detection of an infection based upon indications, we can identify asymptomatic persons who are carriers of the disease of potentially immune. In this way we will protect our teams and promote operability and confidence.
April 24,
2020
4127
We are focused on the satisfaction of our customers’ needs by providing innovative and efficient products and solutions.
In 2019, 718 customers evaluated us, supporting with their opinions and recommendations regarding the quality of our service.